(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
23 September 2021 (23.09.2021)

WIPO | PCT

(10) International Publication Number
WO 2021/189008 A1

(51) International Patent Classification:
C07K 14/47 (2006.01) *C07K 14/705* (2006.01)
A61K 39/00 (2006.01) *C07K 14/71* (2006.01)
C07K 14/005 (2006.01) *C12N 9/12* (2006.01)
C07K 14/725 (2006.01)

(21) International Application Number:
PCT/US2021/023337

(22) International Filing Date:
19 March 2021 (19.03.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/992,806 20 March 2020 (20.03.2020) US
63/137,022 13 January 2021 (13.01.2021) US

(71) Applicant: **LYELL IMMUNOPHARMA, INC.** [US/US]; 400 East Jamie Court, Suite 301, South San Francisco, California 94080 (US).

(72) Inventors: **MOFFETT, Howell Franklin**; c/o Lyell Immunopharma, Inc., 400 East Jamie Court, Suite 301, South San Francisco, California 94080 (US). **LAJOIE, Marc Joseph**; c/o Lyell Immunopharma, Inc., 400 East Jamie Court, Suite 301, South San Francisco, California 94080 (US). **BOYKEN, Scott Edward**; c/o Lyell Immunopharma, Inc., 400 East Jamie Court, Suite 301, South San Francisco, California 94080 (US).

(74) Agent: **LI, Z. Ying** et al.; Steptoe & Johnson LLP, 1330 Connecticut Avenue, N.W., Washington, District of Columbia 20036 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:
— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
— *with sequence listing part of description (Rule 5.2(a))*

(54) Title: NOVEL RECOMBINANT CELL SURFACE MARKERS

(57) Abstract: The present disclosure relates to EGFR-derived polypeptides containing short juxtamembrane sequences, nucleic acids encoding them, and methods of using them to improve cell surface expression of truncated EGFR markers.

WO 2021/189008 A1